benign%20prostatic%20hyperplasia
BENIGN PROSTATIC HYPERPLASIA
Benign prostatic hyperplasia (BPH) is a histopathological diagnosis characterized by epithelial cell & smooth muscle cell proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, which may result in lower urinary tract symptoms, including voiding and storage symptoms.
It is commonly called enlarged prostate.
Etiology is unknown but due to its similarity to the embryonic morphogenesis of the prostate has led to the hypothesis that BPH may be the result of "reawakening" in adulthood of embryonic induction processes.

Introduction

  • Histopathological diagnosis characterized by epithelial cell & smooth muscle proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, w/c may result in lower urinary tract symptoms, including voiding & storage symptoms
  • Common disease of aging men
  • Two phases where prostate doubles its size:
    • At puberty
    • 25 yr old & beyond

Etiology

  • The exact cause of benign prostatic hyperplasia (BPH) is still not well understood

Signs and Symptoms

  • Dribbling at the end of urination
  • Nocturia
  • Pain after ejaculation or urination
  • Weak or interrupted urine stream
  • Trouble starting a urine stream
  • Urinary frequency
  • Urinary urgency
  • Urinary retention
  • Urinary incontinence
  • Urine w/ unusual smell or color

Risk Factors

  • Age 40 years old & older
  • Family history of benign prostatic hyperplasia (BPH)
  • Medical conditions such as obesity, heart & circulatory disease, type 2 diabetes mellitus (DM)
  • Lack of physical exercise
Editor's Recommendations
Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
14 Nov 2017
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
28 Nov 2017
The use of oral androgen receptor inhibitor enzalutamide may benefit chemotherapy-naïve patients with metastatic castration-resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden, signifying that targeting the androgen receptor signalling pathway is a therapeutic option in similar patients, suggests a recent study.
22 Nov 2017
Wet nights appear to occur with considerable frequency in children with monosymptomatic nocturnal enuresis and normal maximal voided volumes (MVV), with a nocturnal urine production well below their MWV and even <65 percent of estimated bladder capacity, according to a study.